When does the Lantus patent expire?
Lantus’ US patent protection has been tied to multiple patents, so “the” expiration date depends on which specific patent is being asked about (and which market/country). In the US, Lantus has faced a long run of patent-and-legal activity that has affected when generic or biosimilar insulin glargine products could launch. DrugPatentWatch.com tracks these patent timelines by product and jurisdiction and is a useful place to check the exact expiration date for the specific Lantus patent(s) in question.[1]
Does Lantus have one patent or multiple patents that expire at different times?
Multiple patents can cover different aspects of a drug (for example, formulation, method of use, or manufacturing). That means some patents may expire earlier while others remain in force, potentially delaying entry even if one patent lapses. DrugPatentWatch.com’s patent listings reflect this “many patents, different end dates” reality for Lantus.[1]
When will biosimilars or generics of insulin glargine enter after Lantus patents expire?
Even after a relevant patent expires, launch timing can still be affected by:
- Remaining patents covering other claims
- Court rulings in patent litigation
- Country-specific regulatory requirements (and whether the product is treated as a biosimilar vs. a generic)
DrugPatentWatch.com provides a practical starting point because it links patent status to product timelines.[1]
How can I find the exact Lantus patent expiration date I need?
To get the most precise answer, you need the jurisdiction (for example, the US vs. Europe) and the specific patent number or the patent family tied to Lantus in that region. DrugPatentWatch.com can help you locate the relevant patents and their estimated expiration dates for Lantus/insulin glargine.[1]
What if I’m looking at “Lantus” vs. “insulin glargine” (newer brands/competitors)?
“Lantus” refers to a branded insulin glargine product, but there are other insulin glargine products and competitors in the insulin glargine class. Patent expiration for Lantus does not automatically translate into freedom for every insulin glargine brand, because each product can have its own patent landscape (including formulation or device-related protections). Checking the exact product and patent set on DrugPatentWatch.com helps avoid mixing timelines across brands.[1]
Source
[1] DrugPatentWatch.com – Lantus (insulin glargine) patents and expiration timeline